Bioequivalence testing of immunosuppressants: concepts and misconceptions.
Immunosuppressants are considered critical dose/narrow therapeutic index drugs and there is the lingering suspicion among physicians and patients that generic versions may differ in quality and therapeutic efficacy from the brand name drug. The innovator's and the generic active drug molecule are exactly the same and are produced following exactly the same tight rules of good manufacturing practice. Upon oral administration, the drug molecule separates from the formulation and passes the membranes of gut mucosa cells; from this point on, the formulation has no influence on the kinetics of a drug and its biological effects. As formulations may differ, bioequivalence testing in healthy volunteer studies establishes equal relative oral bioavailability. Due to the number of patients required to achieve sufficient statistical power, to test the therapeutic equivalence of two formulations of the same drug with the same bioavailability is an unrealistic goal. An often overlooked fact is that the approval by drug regulatory agencies of several post-approval versions of the innovators' immunosuppressants is based on the identical guidelines used for approval of generics. The FDA has issued specific guidelines describing the requirements for approval of generic versions of tacrolimus, sirolimus, and mycophenolic acid. The standard average bioequivalence approach is recommended and in the cases of tacrolimus and sirolimus, the effect of food should also be tested. No studies in the patient population are requested. Immunosuppressants are not regarded as drugs that require a special status to establish bioequivalence between generic and the innovator's versions.
Christians
Uwe
U
Clinical Research and Development, Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado 80045-7503, USA. uwe.christians@ucdenver.edu
Klawitter
Jelena
J
Clavijo
Claudia F
CF
D001682:Biological Availability; D017277:Drug Approval / Q000379:methods*; D016568:Drugs, Generic / Q000592:standards*; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics*; D009173:Mycophenolic Acid / Q000493:pharmacokinetics; D020123:Sirolimus / Q000493:pharmacokinetics; D016559:Tacrolimus / Q000493:pharmacokinetics; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration
D016568:Drugs, Generic; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus